What Makes RAPT Therapeutics (RAPT) an Investment Choice?

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the quarter the fund returned 9.15% (net), compared to a 12.75% return for the Russell 2000 Growth Index. For the year, the fund returned 15.96% (net) compared to 18.66% for the index. In addition, please check the fund’s top five holdings to know its best picks in 2023.

TimesSquare Capital U.S. Small Cap Growth Strategy featured stocks like RAPT Therapeutics, Inc. (NASDAQ:RAPT) in the fourth quarter 2023 investor letter. Headquartered in South San Francisco, California, RAPT Therapeutics, Inc. (NASDAQ:RAPT) is a clinical-stage immunology-based biopharmaceutical company. On March 21, 2024, RAPT Therapeutics, Inc. (NASDAQ:RAPT) stock closed at $8.51 per share. One-month return of RAPT Therapeutics, Inc. (NASDAQ:RAPT) was -2.41%, and its shares lost 51.23% of their value over the last 52 weeks. RAPT Therapeutics, Inc. (NASDAQ:RAPT) has a market capitalization of $296.128 million.

TimesSquare Capital U.S. Small Cap Growth Strategy stated the following regarding RAPT Therapeutics, Inc. (NASDAQ:RAPT) in its fourth quarter 2023 investor letter:

“We also began a position in RAPT Therapeutics, Inc. (NASDAQ:RAPT), a developmental biotechnology company focused on inflammation and immunology therapies. RAPT’s primary treatment, Zelnecirnon, is in late clinical trials to address moderate to severe atopic dermatitis (eczema) with a differentiated oral treatment compared with the current injectable therapies. Results from the current trial are expected in mid-2024, and early indications have been promising. Since our initial purchase, RAPT’s shares rose 51% during the balance of the quarter.”

A scientist in a state-of-the-art laboratory handling biopharmaceutical compounds.

RAPT Therapeutics, Inc. (NASDAQ:RAPT) is not on our list of 30 Most Popular Stocks Among Hedge Funds. At the end of the fourth quarter, RAPT Therapeutics, Inc. (NASDAQ:RAPT) was held by 24 hedge fund portfolios, compared to 20 in the previous quarter, according to our database. In addition, please check out our hedge fund investor letters Q4 2023 page for more investor letters from hedge funds and other leading investors.

Suggested Articles:

• 11 Stocks that Paid Special Dividends in 2024
• 12 Best Emerging Markets Stocks to Buy According to Analysts
• 16 Best Passive Income Stocks To Buy According to Hedge Funds

Disclosure: None. This article is originally published at Insider Monkey.